Sign up now!
Don't show this again
Sweepstakes Rules

We’re glad you’re enjoying Poultry Health Today.
Access is free but you’ll need to register to view more content.
Already registered? Sign In
Tap to download the app
REPORTSCollect articles and features into your own report to read later, print or share with others

Create a New Report


Read Later

Create a new report

Report title (required) Brief description (optional)
follow us

You must be logged in to edit your profile.

Sponsored by Zoetis

Sponsored By Zoetis


Non-ionophore anticoccidial may help manage necrotic enteritis in RWA flocks

Flocks raised without antibiotics (RWA) that received a non-ionophore anticoccidial after coccidiosis vaccination had fewer necrotic enteritis (NE) lesions, less mortality and better feed conversion when exposed to a Clostridium perfringens challenge in a recent controlled study presented at the 2017 International Poultry Scientific Forum.1

In this study, investigators spray-vaccinated more than 1,500 chicks with an attenuated coccidia vaccine at hatch, then divided them into treatment groups. Each group then received either Deccox® (decoquinate), Robenz® (robenidine hydrochloride) or Zoamix® (zoalene) between 14 and 28 days of age as part of a bio-shuttle program.

One additional group received no feed additive and served as a control, and another group received bacitracin methylene disalicylate (BMD), which is indicated for NE prevention, said Manuel Da Costa, DVM, PhD, of Zoetis.

At 16 days of age, the investigators challenged the birds with C. perfringens isolated from a field outbreak, he said.

Improved FCR

Compared to non-medicated controls, feed-conversion ratio (FCR) improved by 3 points in birds that received Zoamix and by 2 points in birds that received Robenz. The anticoccidial Deccox resulted in the best bodyweight of the three non-ionophore anticoccidials.

Birds in all three of these treatment groups also had reduced mortality reflected by a reduced incidence of severe NE lesions. Severe lesions were reduced by 17% in the Deccox group, by 26% in the Robenz group and by 27% in the Zoamix group when compared to non-medicated controls, Da Costa said of the study, conducted by Zoetis in collaboration by with Colorado Quality Research.

Not surprisingly, BMD resulted in the best FCR — 5 points — the best bodyweight gain, and the fewest NE lesions as well as the lowest mortality, he said.

NE is perhaps the greatest challenge to successful RWA production and tends to occur with coccidial cycling in the presence of C. perfringens, a cause of NE. Coccidia cycling along with C. perfringens challenge can increase the severity of NE lesions as well as NE-related mortality, Da Costa explained. RWA production systems have to rely on vaccines, non-ionophore anticoccidials or a combination of both — a bio-shuttle program — to prevent coccidiosis.

Compared to non-medicated controls, birds in this study that received non-ionophore anticoccidials had significantly (p<.05) reduced mortality as well as numerically improved feed conversion and reduced NE lesions, thereby suggesting good potential for use in bio-shuttle programs designed for flocks raised without antibiotics, Da Costa concluded.

1Da Costa M, et al. Effects of various anticoccidials as bio-shuttle alternatives for broilers under a necrotic enteritis challenge. 2017 International Poultry Scientific Forum. Atlanta, Georgia.

Editor’s note: This video interview, podcast and news article were developed independently by the editors of Poultry Health Today. They are presented here solely for their news value. The opinions and recommendations presented are not necessarily shared by the editors of Poultry Health Today or the interviewee’s employer. 

Posted on December 25, 2017

tags: , , , ,

You must be logged in to edit your profile.

Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.